Clinical Psychopharmacology · Paper A
Drug selection (clinical)
Drug selection questions matter because exam vignettes reward matching a patient's clinical picture to the correct step of the treatment guideline's ladder, not just naming any plausible drug. Exam vignettes describe a patient and ask for the first-line choice or the next step, often with distractors that are simply 'another drug of the same class'. For example, imagine a patient who has failed two adequate antipsychotic trials, the answer is clozapine, not a third antipsychotic of the same class. In practice, this means checking whether prior treatment was already adequate, not just whether a drug from the class has been tried.
Key ladders to knowIn schizophreniaA long-term mental illness involving episodes of psychosis such as hallucinations and delusions.Read more →, try two antipsychotics (at least one second-generation) at an adequate dose and for long enough; if both fail (treatment resistance), use clozapine, the only drug proven in resistant illness, which needs regular blood-count (FBCFull blood count, a blood test that measures red cells, white cells and platelets.Read more →, full blood count) monitoring. In OCDObsessive-compulsive disorder, a condition of unwanted repeated thoughts and the actions done to relieve them.Read more → (obsessive-compulsive disorder), use an SSRISelective serotonin reuptake inhibitor, a common type of antidepressant.Read more → (selective serotonin reuptake inhibitor), often at a higher dose, plus CBTCognitive behavioural therapy, a talking therapy that works on the link between thoughts, feelings and actions.Read more → (cognitive behavioural therapy, a structured talking therapy) with exposure and response prevention; clomipramine is second-line. In depression, an SSRI is first-line. In GADGeneralised anxiety disorder, persistent, hard-to-control worry across many areas of life.Read more → (generalised anxiety disorder), an SSRI or SNRISerotonin-noradrenaline reuptake inhibitor, an antidepressant that raises two brain chemicals instead of one.Read more → (serotonin-noradrenaline reuptake inhibitor) is first-line, not a long-term benzodiazepine. Picture a patient with GAD started on a long-term benzodiazepine instead of an SSRI. Practically, matching the diagnosis in the stem to its specific ladder, since the wrong ladder gives a plausible-looking but wrong answer.
Two candidates can both know every drug in a psychiatric formulary and still get a "which drug next" question wrong, because the skill being tested is not drug knowledge in isolation: it is matching a specific clinical picture to the correct step of a specific guideline ladder. Exam distractors are deliberately built from real drugs used for the right condition at the wrong step, or the right step for the wrong condition.
FIRST-LINE treatment means the option a guideline recommends trying before anything else, usually because it has the best balance of proven efficacy and acceptable side effects. TREATMENT-RESISTANT (or treatment-refractory) describes an illness that has not responded despite an adequate trial (the right dose, for long enough) of standard options, not simply "tried one drug briefly". AUGMENTATION means adding a second drug to boost the effect of the first, rather than switching to a different drug entirely.
A common trap is assuming that trying any drug from the right class satisfies the guideline step. Suppose a stem describes a patient who took an antipsychotic for four days before stopping due to mild nausea: this is not an adequate trial, and moving straight to clozapine would be premature. The step only counts once the dose and duration were genuinely adequate.
Guidelines exist because trial evidence in large populations, not individual preference, should drive the default choice; that is the whole point of an evidence-based ladder. Each condition has its own ladder built from its own trial evidence, so the ladder for cannot be borrowed to answer a stem about generalised anxiety disorder, even though both may mention an antipsychotic somewhere on their respective ladders.
In , guidance recommends trying two antipsychotics, at least one a second-generation agent, each at an adequate dose for an adequate duration; if both fail, clozapine is the only agent with proven efficacy in treatment-resistant illness, and it requires regular full blood count monitoring for agranulocytosis. In depression, an is first-line. In obsessive-compulsive disorder, an SSRI, often at a higher dose than for depression, combined with cognitive behavioural therapy using exposure and response prevention, is first-line; clomipramine is second-line. In generalised anxiety disorder, an SSRI or an (serotonin-noradrenaline reuptake inhibitor) is first-line. A long-term benzodiazepine is not, because of dependence risk. In bipolar disorder and in pregnancy, sodium valproate should be avoided; lamotrigine or an antipsychotic is generally preferred instead.
Do not confuse "another drug of the same class" with "the guideline's actual next step": a stem naming a second after an adequate SSRI trial has failed for depression may be testing whether the candidate knows that switching class, or augmenting, is the next recommended move. Do not confuse rapid tranquillisation of acute agitation, which is an emergency protocol, with routine maintenance drug selection; NICE guidance on rapid tranquillisation favours intramuscular lorazepam, or intramuscular haloperidol combined with promethazine, with flumazenil (a benzodiazepine antidote) and procyclidine (for acute , a sudden sustained muscle spasm) available.
Correct drug selection starts with getting the diagnosis right, since the whole ladder hangs off it: a patient with psychotic depression is managed differently from one with pure psychosis, and a patient with anxiety secondary to a physical illness needs that illness addressed rather than an anxiolytic alone. Assessment should also weigh prior treatment history, both in the patient and in first-degree relatives, since a previous good response to a specific drug is a useful predictor.
Beyond the diagnosis-specific ladder, management weighs the individual patient: side-effect profile against comorbidity (avoiding -interval-prolonging drugs in cardiac disease, for example), sedating agents for a patient with severe insomnia, weight-neutral agents where obesity is already a concern, and patient preference where several options are genuinely equivalent. The Maudsley Prescribing Guidelines and BNF (British National Formulary) are the standard UK references for dosing detail once the guideline step is chosen.
Two failed adequate antipsychotic trials means clozapine, not a third antipsychotic. (generalised anxiety disorder) means an or , not a long-term benzodiazepine. Pregnancy or bipolar disorder means avoiding valproate. Acute agitation needing rapid tranquillisation is a different clinical problem from routine first-line selection, with its own separate protocol.
Drug selection questions are really guideline-matching questions: identify the diagnosis, find its specific ladder, confirm whether the current step counts as an adequate trial, and only then pick the next recommended option, watching for distractors that are simply another drug from the same class rather than the guideline's true next step.